Quick filters:
Open Data
Open Code
Pre-registered
Funding Declared
COI Declared
Open Access
Clear Filters
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the im…
Vose JM; Fu K; Wang L; Mansoor A; Stewart D; Cheng H; Smith L; Yuan J; Qureishi HN; Link BK; Cessna MH; Barr PM; Kahl BS; Mckinney MS; Khan N; Advani RH; Martin P; Goy AH; Phillips TJ; Mehta A; Kamdar M; Crump M; Pro B; Flowers CR; Jacobson CA; Smith SM; Stephens DM; Bachanova V; Jin Z; Wu S; Hernandez-Ilizaliturri F; Torka P; Anampa-Guzmán A; Kashef F; Li X; Sharma S; Greiner TC; Armitage JO; Lunning M; Weisenburger DD; Bociek RG; Iqbal J; Yu G; Bi C; North American Mantle Cell Lymphoma Consortium.
J Hematol Oncol
(Unknown)
Published: 2023
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-…
Seckinger A; Majocchi S; Moine V; Nouveau L; Ngoc H; Daubeuf B; Ravn U; Pleche N; Calloud S; Broyer L; Cons L; Lesnier A; Chatel L; Papaioannou A; Salgado-Pires S; Krämer S; Gockel I; Lordick F; Masternak K; Poitevin Y; Magistrelli G; Malinge P; Shang L; Kallendrusch S; Strein K; Hose D.
J Hematol Oncol
(Unknown)
Published: 2023
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned.
López de Sá A; Díaz-Tejeiro C; Poyatos-Racionero E; Nieto-Jiménez C; Paniagua-Herranz L; Sanvicente A; Calvo E; Pérez-Segura P; Moreno V; Moris F; Ocana A.
J Hematol Oncol
(Unknown)
Published: 2023
CRISPR screening in hematology research: from bulk to single-cell level.
J Hematol Oncol
(Unknown)
Published: 2023
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.
J Hematol Oncol
(Unknown)
Published: 2023
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease.
Heitmann JS; Schlenk RF; Dörfel D; Kayser S; Döhner K; Heuser M; Thol F; Kapp-Schwoerer S; Labrenz J; Edelmann D; Märklin M; Vogel W; Bethge W; Walz JS; Große-Hovest L; Steiner M; Jung G; Salih HR.
J Hematol Oncol
(Unknown)
Published: 2023
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for re…
Rejeski K; Hansen DK; Bansal R; Sesques P; Ailawadhi S; Logue JM; Bräunlein E; Cordas Dos Santos DM; Freeman CL; Alsina M; Theurich S; Wang Y; Krackhardt AM; Locke FL; Bachy E; Jain MD; Lin Y; Subklewe M.
J Hematol Oncol
(Unknown)
Published: 2023
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after…
Short NJ; Muftuoglu M; Ong F; Nasr L; Macaron W; Montalban-Bravo G; Alvarado Y; Basyal M; Daver N; Dinardo CD; Borthakur G; Jain N; Ohanian M; Jabbour E; Issa GC; Qiao W; Huang X; Kanagal-Shamanna R; Patel KP; Bose P; Ravandi F; Delumpa R; Abramova R; Garcia-Manero G; Andreeff M; Cortes J; Kantarjian H.
J Hematol Oncol
(Unknown)
Published: 2023
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced …
Tassone P; Di Martino MT; Arbitrio M; Fiorillo L; Staropoli N; Ciliberto D; Cordua A; Scionti F; Bertucci B; Salvino A; Lopreiato M; Thunarf F; Cuomo O; Zito MC; De Fina MR; Brescia A; Gualtieri S; Riillo C; Manti F; Caracciolo D; Barbieri V; Di Paola ED; Di Francesco AE; Tagliaferri P.
J Hematol Oncol
(Unknown)
Published: 2023
Small RNA modifications: regulatory molecules and potential applications.
J Hematol Oncol
(Unknown)
Published: 2023